Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-05

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Surgical Treatment Strategies for Moderate Ischemic Mitral Regurgitation

NCT06408779

Mitral Valve Insufficiency Mitral Valve Annuloplasty Coronary Artery Bypass

COMPLETED

Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China

NCT07230756

Ischemic Mitral Regurgitation Coronary Heart Disease (CHD)

NOT_YET_RECRUITING

Mitral Valve Repair Combined Coronary Artery Bypass Grafting(CABG) Verus CABG Alone on Functional Ischemic Mitral Regurgitation

NCT03525041

Coronary Artery Disease Mitral Valve Insufficiency

UNKNOWN NA

Early Treatment of ARNI on Myocardial Remodeling and Progress

NCT04342351

Myocardial Infarction

UNKNOWN PHASE4

Sodium Creatine Phosphate in Heart Valve Surgery

NCT03186053

Heart Valve Diseases

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Ischemic Mitral Regurgitation Angiotensin Receptor/Neprilysin Inhibitor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group: isolated CABG

Group Type NO_INTERVENTION

No interventions assigned to this group

Sacubitril/valsartan therapy after isolated CABG

Group Type EXPERIMENTAL

sacubitril/valsartan

Intervention Type DRUG

Sacubitril/valsartan therapy after isolated CABG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sacubitril/valsartan

Sacubitril/valsartan therapy after isolated CABG

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Fully informed and voluntarily signed informed consent;
2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )

Exclusion Criteria

1.Symptomatic hypotension and/or a SBP \< 100 mmHg at screening; 2.Estimated GFR \< 30 mL/min/1.73m2; 3.Serum potassium \> 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No